Infensa Bioscience is pioneering therapeutic solutions to treat the two leading causes of death worldwide – heart attack and stroke – by converting one of nature’s oldest weapons into life-saving medicine.
Inspired by a peptide from the K’gari funnel-web spider, Infensa’s drug candidates block the signal that prompts oxygen-starved cells to die during heart attacks or strokes.
After securing A$23m to launch Infensa Bioscience, the company licensed the game-changing research from UQ’s Institute for Molecular Bioscience, and joined TRI in 2022 to develop what could be the world’s first cardioprotective drug. With government funding set to support human trials in 2025, this breakthrough may transform emergency cardiac care by boosting survival rates and post-attack quality of life, while extending donor heart viability during heart transplantation.
18 million
lives at risk annually
A$23m
secured for development
4-year
clinical trial program funded
